FIELD: biotechnology.
SUBSTANCE: invention relates to fused proteins, and can be used in medicine for inhibiting tumor growth. A fused protein comprising an immunoglobulin Fc region is obtained; and a version of ligand-3 of type CC (CCL3) having sequence SEQIDNO: 3, in which A or AP N-terminus are deleted and aspartic acid in amino acid position 27 from the N-terminus of CCL3 is replaced with alanine. In the obtained fused protein construct, the CCL3 variant is linked to the Fc immunoglobulin region through a linker, containing sequence SEQIDNO: 5, in order from N-terminus to C-terminal: version of CCL3, linker, immunoglobulin Fc region.
EFFECT: invention enables to obtain a fused protein having binding activity CCL3.
9 cl, 5 tbl, 4 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED MOLECULE CAPABLE OF INDUCING NON-INFLAMMATORY PHAGOCYTOSIS | 2022 |
|
RU2823919C1 |
| FGF21 FUSED WITH LONG-ACTING PROTEINS AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2741087C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| FUSION PROTEIN CONTAINING HUMAN LEFTY A PROTEIN VARIANTS AND ITS USE | 2019 |
|
RU2793631C2 |
| PROTEINS WITH A DOUBLE FUNCTION AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2016 |
|
RU2741345C2 |
| PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF HEPATITIS, LIVER FIBROSIS AND LIVER CIRRHOSIS, INCLUDING FUSION PROTEINS | 2017 |
|
RU2795548C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
| COMPOSITION FOR CULTURING REGULATORY T-CELLS AND ITS APPLICATION | 2020 |
|
RU2807802C1 |
| MICROORGANISM OF CORYNEBACTERIUM GENUS, PRODUCING L-AMINO ACIDS, AND METHOD OF PRODUCING L-AMINO ACIDS USING SAME | 2022 |
|
RU2824668C1 |
